Cancer Chemotherapy and Pharmacology

, Volume 20, Issue 3, pp 235–238 | Cite as

Acetylation and oxidation phenotypes in malignant lymphoma

  • Philip A. Philip
  • Howard J. Rogers
  • Peter G. Harper
Original Articles Acetylation Phenotype, Malignant Lymphoma

Summary

101 white British adults with Hodgkin's disease or non-Hodgkin's lymphoma were phenotyped for acetylation status using dapsone and for oxidation status with debrisoquine prior to treatment. The frequencies of acetylation and oxidation phenotypes in these patients were compared with reference populations of normal subjects. No significant difference in phenotype frequency was found in the lymphoma patients. This suggests that neither of these metabolic polymorphisms for exogenous compounds is strongly associated with these malignancies. Owing to the small size of the study, however, an effect of these phenotypes could not be excluded.

Keywords

Lymphoma Cancer Research Oxidation Status Reference Population Malignant Lymphoma 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Armitage P (1971) Statistical methods in medical research, 1st edn. Blackwell, OxfordGoogle Scholar
  2. 2.
    Blair A, Hayes HM (1980) Causes of death among US veterinarians 1966–1977. Int J Cancer 25:181Google Scholar
  3. 3.
    Broder S (1984) T-cell lymphoproliferative syndrome associated with human T-cell leukaemia/lymphoma virus. Ann Int Med 100:543Google Scholar
  4. 4.
    Bulovskaya LN, Krupkin RG, Bochina TA, Shipkova AA, Pavlova MV (1978) Acetylator phenotype in patients with breast cancer. Oncology 35: 185Google Scholar
  5. 5.
    Cartwright RA, Glashan RW, Rogers HJ, Ahmad RA, Barham-Hall D, Higgins E, Kahn MA (1982) Role of N-acetyltransferase phenotypes in bladder carcinogenesis: a pharmacogenetic epidemiological approach to bladder cancer. Lancet 2:842Google Scholar
  6. 6.
    Cartwright RA, Philip PA, Rogers HJ, Glashan RW (1984) Genetically determined debrisoquine oxidation capacity in bladder cancer. Carcinogenesis 5:1191Google Scholar
  7. 7.
    Chiazzi L, Nichols WE, Wong O (1977) Mortality among employees of PVC fabricators. J Occup Med 19:623Google Scholar
  8. 8.
    Clark DWJ (1985) Genetically determined variability in acetylation and oxidation: therapeutic implications. Drugs 29: 342Google Scholar
  9. 9.
    Cunningham AS (1976) Lymphomas and animal protein consumption. Lancet 2:1184Google Scholar
  10. 10.
    Evans DAP, Eze LC, Whibley EJ (1983) The association of the slow acetylator phenotype with bladder cancer. J Med Genet 26:243Google Scholar
  11. 11.
    Glowinski IB, Radtke HE, Weber WW (1978) Genetic variation in N-acetylation of carcinogenic arylamines by human and rabbit liver. Mol Pharmacol 14:940Google Scholar
  12. 12.
    Hanson A, Melander A, Wahlin-Boll E (1981) Acetylator phenotyping: a comparison of the isoniazid and dapsone tests. Eur J Clin Pharmacol 20:233Google Scholar
  13. 13.
    Hardell L (1979) Malignant lymphoma of histiocytic type and exposure to phenoxyacetic acids or chlorophenols. Lancet 1: 55Google Scholar
  14. 14.
    Hetzel MR, Law M, Keal EE, Sloan TP, Idle JR, Smith RL (1980) Is there a genetic component in bronchial carcinoma in smokers? Thorax 35:709Google Scholar
  15. 15.
    Hutchings A, Monie RD, Spragg B, Routledge PA (1984) Acetylator phenotyping: the effect of ethanol on the dapsone test. Br J Clin Pharmacol 18:98Google Scholar
  16. 16.
    Idle JR, Mahgoub A, Sloan TP, Smith RL, Mbanefo CO, Bababunmi EA (1981) Some observations on the oxidation phenotype status of Nigerian patients presenting with cancer. Cancer Lett 11:331Google Scholar
  17. 17.
    Illett KF, David BM, D'Etchon P, Castleden WM, Kwa R (1986) Acetylation status in patients with colorectal cancer. Acta Pharmacol Toxicol 59 [Suppl V]:220Google Scholar
  18. 18.
    Lennard MS, Silas JH, Smith AJ, Tucker GT (1977) Determination of debrisoquine and its 4-hydroxy metabolite in biological fluids by gas chromatography with flame-ionisation and nitrogen-selective detection. J Chromatogr 133:161Google Scholar
  19. 19.
    Li FP, Fraumeni JF, Mantel N, Miller RW (1969) Cancer mortality among chemists. J Natl Cancer Inst 43:1159Google Scholar
  20. 20.
    Li FP, Willard DR, Goodman R, Vawter G (1975) Malignant lymphoma after diphenylhydantoin (Dilantin) therapy. Cancer 36:1359Google Scholar
  21. 21.
    Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL (1977) Polymorphic hydroxylation of debrisoquine in man. Lancet 2:584Google Scholar
  22. 22.
    Monson RR, Nakano KK (1976) Mortality among rubber workers. Am J Epidemiol 103:284Google Scholar
  23. 23.
    Olin GR (1978) The hazards of a chemical laboratory environment-a study of the mortality in two cohorts of Swedish chemists. Am Ind Hyg Assoc J 39:557Google Scholar
  24. 24.
    Philip PA, Roberts MS, Rogers HJ (1984) A rapid method for determination of acetylation phenotype using dapsone. Br J Clin Pharmacol 17:465Google Scholar
  25. 25.
    Philip PA, Gayed SL, Rogers HJ, Crome P (1987) Influence of age, sex and body weight on the dapsone acetylation phenotype. Br J Clin Pharmacol 23:709Google Scholar
  26. 26.
    Pontiroli AE, De Pasqua A, Bonisolli L, Pozza G (1985) Aging and acetylator phenotype as determined by administration of sulphadimidine. Eur J Clin Pharmacol 28:485Google Scholar
  27. 27.
    Ritter J, Somasundaram R, Heinemeyer G, Roots I (1986) The debrisoquine hydroxylation phenotype and the acetylator phenotype as genetic risk factors for the occurrence of larynx and pharynx carcinoma. Acta Pharmacol Toxicol 59 [Suppl V]: 221Google Scholar
  28. 28.
    Searle CE (1978) Epidemiological study of the mortality of British chemists. Br J Cancer 38:192–193Google Scholar
  29. 29.
    Steiner E, Iselius L, Alvan G, Lindsten J, Sjöqvist F (1985) A family study of genetic and environmental factors determining polymorphic hydroxylation of debrisoquine. Clin Pharmacol Ther 38:394Google Scholar
  30. 30.
    Weber WW, Hein DW (1985) N-Acetylation pharmacogenetics. Pharmacol Rev 37:25Google Scholar

Copyright information

© Springer-Verlag 1987

Authors and Affiliations

  • Philip A. Philip
    • 1
  • Howard J. Rogers
    • 1
  • Peter G. Harper
    • 2
  1. 1.Department of Clinical PharmacologyUnited Medical and Dental Schools, Guy's HospitalLondonUK
  2. 2.Department of Medical OncologyUnited Medical and Dental Schools, Guy's HospitalLondonUK

Personalised recommendations